levofloxacin has been researched along with rofecoxib in 5 studies
| Studies (levofloxacin) | Trials (levofloxacin) | Recent Studies (post-2010) (levofloxacin) | Studies (rofecoxib) | Trials (rofecoxib) | Recent Studies (post-2010) (rofecoxib) |
|---|---|---|---|---|---|
| 4,346 | 581 | 2,209 | 1,914 | 307 | 163 |
| Protein | Taxonomy | levofloxacin (IC50) | rofecoxib (IC50) |
|---|---|---|---|
| Prostaglandin G/H synthase 2 | Bos taurus (cattle) | 0.43 | |
| Cytochrome c oxidase subunit 2 | Homo sapiens (human) | 1.51 | |
| Prostaglandin G/H synthase 1 | Ovis aries (sheep) | 0.5 | |
| Seed linoleate 13S-lipoxygenase-1 | Glycine max (soybean) | 0.5 | |
| Calpain-2 catalytic subunit | Homo sapiens (human) | 0.02 | |
| Prostaglandin G/H synthase 1 | Homo sapiens (human) | 1.8 | |
| Prostaglandin G/H synthase 2 | Homo sapiens (human) | 0.3602 | |
| Prostaglandin G/H synthase 2 | Rattus norvegicus (Norway rat) | 0.76 | |
| Prostaglandin G/H synthase 2 | Ovis aries (sheep) | 0.486 | |
| Prostaglandin G/H synthase 2 | Mus musculus (house mouse) | 0.036 | |
| Sodium-dependent serotonin transporter | Macaca mulatta (Rhesus monkey) | 0.5 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (40.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Andricopulo, AD; Moda, TL; Montanari, CA | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Choi, SS; Contrera, JF; Hastings, KL; Kruhlak, NL; Sancilio, LF; Weaver, JL; Willard, JM | 1 |
| Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
5 other study(ies) available for levofloxacin and rofecoxib
| Article | Year |
|---|---|
Hologram QSAR model for the prediction of human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Holography; Humans; Models, Biological; Models, Molecular; Molecular Structure; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2007 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Topics: | 2008 |
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship | 2012 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |